Business Context and Reporting Period
This Form 8-K is a current report filed by Sonus Pharmaceuticals, Inc. (not Achieve Life Sciences, Inc.) on September 15, 2004. The filing discloses the entry into a material definitive agreement and the appointment of a principal officer.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- Executive Appointment: Alan Fuhrman was appointed as Senior Vice President and Chief Financial Officer effective September 15, 2004.
- Compensation Agreement: A Change in Control Agreement was executed with Mr. Fuhrman. It stipulates that if his employment is terminated within 12 months of a change in control (voluntarily for good reason or involuntarily without cause), he will receive accrued salary, unpaid incentive compensation, and a severance payment equal to his highest annual base salary in effect within 12 months of termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, or discussion of general business risks. The primary contingency disclosed is the specific severance obligation triggered by a change in control event within one year of Mr. Fuhrman's appointment.
Investor Verification Checklist
- Verify the exact terms of the Change in Control Agreement (Exhibit 10.1) regarding the definition of "good reason" and "change in control."
- Confirm Mr. Fuhrman's prior employment history at Integrex, Inc. and Capital Stream, Inc. as stated in the filing.
- Review the accompanying press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.